Prospective evaluation of the effect of short-term oral vitamin d supplementation on peripheral neuropathy in type 2 diabetes mellitus

D Shehab, Khaled Al-Jarallah, Nabila Abdella, Olusegun A Mojiminiyi, Hisham Al Mohamedy, D Shehab, Khaled Al-Jarallah, Nabila Abdella, Olusegun A Mojiminiyi, Hisham Al Mohamedy

Abstract

Objective: We aimed to assess the efficacy of short-term oral vitamin D supplementation on peripheral neuropathy in patients with type 2 diabetes.

Materials and methods: This prospective, placebo-controlled trial included 112 type 2 diabetic patients with diabetic peripheral neuropathy (DPN) and vitamin D [25(OH)D] deficiency. Patients were sequentially assigned to a treatment group (n = 57) and a placebo group (n = 55). DPN was assessed using a neuropathy symptom score (NSS), a neuropathy disability score (NDS) and a nerve conduction study (NCS). Vitamin D status was determined by measuring the serum total 25(OH)D concentration. Patients received either oral vitamin D3 capsules or starch capsules once weekly for 8 weeks. The primary outcome was changes in NSS and NDS from baseline. The secondary outcome was changes in the NCS result.

Results: Serum 25(OH)D concentrations significantly improved after oral vitamin D supplementation in the treatment group when compared to the placebo group (32.8 ± 23.7 vs. 1.1 ± 3.6, p < 0.0001). Similarly, the improvement in NSS values was significantly greater in the treatment group than in the placebo group (-1.49 ± 1.37 vs. -0.20 ± 0.59, p < 0.001). No improvement was observed for NDS and NCS between the 2 groups after treatment.

Conclusion: Short-term oral vitamin D3 supplementation improved vitamin D status and the symptoms of neuropathy in patients with type 2 diabetes.

Figures

Fig. 1
Fig. 1
Flow chart.

References

    1. Edwards JL, Vincent AM, Cheng HT, et al. Diabetic neuropathy: mechanisms to management. Pharmacol Ther. 2008;120:1–34.
    1. Chaychi L, Mackenzie T, Bilotta D, et al. Association of serum vitamin D level with diabetic polyneuropathy. Med Pract Rev. 2011;2:11–15.
    1. Shehab D, Al-Jarallah K, Mojiminiyi OA, et al. Does vitamin D deficiency play a role in peripheral neuropathy in type 2 diabetes? Diabet Med. 2012;29:43–49.
    1. Soderstrom LH, Johnson SP, Diaz VA, et al. Association between vitamin D and diabetic neuropathy in a nationally representative sample: results from 2001–2004 NHANES. Diabet Med. 2012;29:50–55.
    1. Valensi P, Devehat C, Richard J, et al. A multicenter double blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy: a preliminary report. J Diabetes Complications. 2005;19:247–253.
    1. Lee P, Chen R. Vitamin D as an analgesic for patients with type 2 diabetes and neuropathic pain. Arch Intern Med. 2008;168:771–772.
    1. Bell DS. Reversal of the symptoms of diabetic neuropathy through correction of vitamin D deficiency in a type 1 diabetic patient. Case Rep Endocrinol. 2012;2012:165056.
    1. Standards of Medical Care in Diabetes 2013. Diabetes Care. 2013;36((suppl 1)):S11–S66.
    1. Young MJ, Boulton AJ, Macleod AF, et al. A multicenter study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36:150–154.
    1. Abbott CA, Carrington AL, Ashe H, et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med. 2002;19:377–384.
    1. Malik RA, et al. Corneal confocal microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic patients. Diabetologia. 2003;46:683–688.
    1. Kimura J. Principles of nerve conduction studies. In: Kimura J, editor. Electrodiagnosis in Diseases of Nerve and Muscle: Principles and Practice. ed 2. Philadelphia: Davis; 1989. pp. 78–102.
    1. Kimura J. Principles and pitfalls of nerve conduction studies. Ann Neurol. 1984;16:415–428.
    1. Shehab D. Normative DATA of nerve conduction studies in the upper limb in Kuwait – are they different than the Western data? Med Princ Pract. 1998;7:203–208.
    1. Shehab D, Moussa MA. Normal values of lower limb nerve conduction in Kuwait. II. Med Princ Pract. 1999;8:134–137.
    1. Adams JS, Hewison M. Update in vitamin D. J Clin Endocr Metab. 2010;95:471–478.
    1. Holick MF, Binkley N, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–1930.
    1. Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc. 2003;78:1463–1470.
    1. Carlson AN, Kenny AM. Is vitamin D insufficiency associated with peripheral neuropathy? Endocrinologist. 2007;17:319–325.
    1. Neveu I, Jehan F, Wion D. Alteration in the levels of 1,25-(OH)2D3 and corticosterone found in experimental diabetes reduces nerve growth factor (NGF) gene expression in vitro. Life Sci. 1992;50:1769–1772.
    1. Riaz S, Malcangio M, Miller M, et al. A vitamin D3 derivative (CB1093) induces nerve growth factor and prevents neurotrophic deficits in streptozocinp diabetic rats. Diabetologia. 1999;42:1308–1313.
    1. Fukuoka M, Sakurai K, Ohta T, et al. Tacalcitol, an active vitamin D3, induces nerve growth factor production in human epidermal keratinocytes. Skin Pharmacol Appl Skin Physiol. 2001;14:226–233.
    1. Anand P, Terenghi G, Warner G, et al. The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med. 1996;6:703–707.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere